Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 3, 2012

Waters, NIBRT Partner to Grow Knowledge of Large-Molecule Characterization

The National Institute for Bioprocessing Research and Training (NIBRT) in Ireland and Waters are partnering on training and research to increase large-molecule characterization capacity and knowledge, according to an NIBRT press release.

The National Institute for Bioprocessing Research and Training (NIBRT) in Ireland and Waters are partnering on training and research to increase large-molecule characterization capacity and knowledge, according to an NIBRT press release.

The two organizations established the Complete Product and Processing Characterization Facility for hands-on laboratory-based scientific training and retraining of “fit-for-purpose” biopharmaceutical analysis, including protein and peptide characterization. The goal of the facility is to provide comprehensive training of industry and governmental technicians and scientists in an effort to develop advanced biotherapeutic characterization Training on US and European drug regulations will also be offered. Finally, the partnership establishes NIBRT as a Waters Center of Innovation in the area of glycobiology research.

“Ireland is a leading location globally for the development and manufacture of complex biopharmaceutical drugs. This is due in large part to a sustained commitment to quality and compliance with the highest regulatory standards,” said NIBRT’s Interim Director Prof. Ian Marison.

“Through this lab and other collaborations, Waters will work with industry to improve the development of biopharmaceuticals and inform governments on the types of regulations that should be put in place,” said Mike Harrington, Waters vice-president, European Operations.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.